Reviewing Hyperfine (NASDAQ:HYPR) & MariMed (OTCMKTS:MRMD)

MariMed (OTCMKTS:MRMD) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Valuation & Earnings

This table compares MariMed and Hyperfine”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MariMed	$159.83 million	0.18	-$14.48 million	($0.04)	-1.81
Hyperfine	$16.54 million	4.91	-$35.57 million	($0.38)	-2.01

MariMed has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than MariMed, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MariMed has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Insider & Institutional Ownership

0.2% of MariMed shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 17.3% of MariMed shares are held by company insiders. Comparatively, 26.3% of Hyperfine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares MariMed and Hyperfine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MariMed	-9.13%	-10.71%	-2.58%
Hyperfine	-210.75%	-97.88%	-61.81%

Analyst Ratings

This is a summary of recent ratings and recommmendations for MariMed and Hyperfine, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MariMed	0	2	0	0	2.00
Hyperfine	1	1	3	0	2.40

Hyperfine has a consensus price target of $2.03, indicating a potential upside of 165.80%. Given Hyperfine’s stronger consensus rating and higher possible upside, analysts plainly believe Hyperfine is more favorable than MariMed.

About MariMed

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.